hrcak mascot   Srce   HID

Izvorni znanstveni članak
https://doi.org/10.20471/acc.2018.57.01.07

Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study

Neven Papić ; Department for Viral Hepatitis, Dr. Fran Mihaljević University Hospital for Infectious Diseases, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia
Jelena Budimir ; Department for Viral Hepatitis, Dr. Fran Mihaljević University Hospital for Infectious Diseases, Zagreb, Croatia
Ivan Kurelac ; Department for Viral Hepatitis, Dr. Fran Mihaljević University Hospital for Infectious Diseases, Zagreb, Croatia
Davorka Dušek ; Department for Viral Hepatitis, Dr. Fran Mihaljević University Hospital for Infectious Diseases, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia
Davor Jugović ; School of Medicine, University of Zagreb, Zagreb, Croatia
Nina Krajcar ; Department for Pediatric Infectious Diseases, Dr. Fran Mihaljević University Hospital for Infectious Diseases, Zagreb, Croatia
Adriana Vince ; Department for Viral Hepatitis, Dr. Fran Mihaljević University Hospital for Infectious Diseases, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia

Puni tekst: engleski, pdf (851 KB) str. 61-70 preuzimanja: 167* citiraj
APA 6th Edition
Papić, N., Budimir, J., Kurelac, I., Dušek, D., Jugović, D., Krajcar, N. i Vince, A. (2018). Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study. Acta clinica Croatica, 57. (1.), 61-70. https://doi.org/10.20471/acc.2018.57.01.07
MLA 8th Edition
Papić, Neven, et al. "Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study." Acta clinica Croatica, vol. 57., br. 1., 2018, str. 61-70. https://doi.org/10.20471/acc.2018.57.01.07. Citirano 17.09.2019.
Chicago 17th Edition
Papić, Neven, Jelena Budimir, Ivan Kurelac, Davorka Dušek, Davor Jugović, Nina Krajcar i Adriana Vince. "Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study." Acta clinica Croatica 57., br. 1. (2018): 61-70. https://doi.org/10.20471/acc.2018.57.01.07
Harvard
Papić, N., et al. (2018). 'Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study', Acta clinica Croatica, 57.(1.), str. 61-70. https://doi.org/10.20471/acc.2018.57.01.07
Vancouver
Papić N, Budimir J, Kurelac I, Dušek D, Jugović D, Krajcar N i sur. Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study. Acta clinica Croatica [Internet]. 2018 [pristupljeno 17.09.2019.];57.(1.):61-70. https://doi.org/10.20471/acc.2018.57.01.07
IEEE
N. Papić, et al., "Treatment of Elderly Patients with Chronic Hepatitis C: A Retrospective Cohort Study", Acta clinica Croatica, vol.57., br. 1., str. 61-70, 2018. [Online]. https://doi.org/10.20471/acc.2018.57.01.07

Sažetak
The prevalence of chronic hepatitis C increases in elderly patients. The aims of this study were to identify the factors associated with hepatocellular carcinoma (HCC) and end-stage liver disease development and to evaluate the efficacy and safety of pegylated interferon (PEG-IFNα) plus ribavirin (RBV) therapy in elderly patients. A retrospective cohort study included all consecutive patients with hepatitis C virus (HCV) infection treated with PEG-IFNα+RBV between 2003 and 2013. Elderly patients had a higher frequency of poor prognostic factors including genotype 1 infection, high fibrosis, and high fibrosis index based on four factors (FIB-4) score. The sustained virologic response (SVR) rate for genotype 1 was significantly lower (35.8% vs. 57.1%), while the frequency of PEG-IFNα (27.2% vs. 7.8%), RBV dose reduction (19.6% vs. 9.7%) and treatment discontinuation (13.0% vs. 4.1%) was significantly higher in elderly patients. However, age was not associated with SVR in multivariate analysis, and comparable SVR rates were achieved when adjusted for fibrosis score (Ishak ≤3: 66.7% vs. 69.8%). During the follow-up, HCC was diagnosed in 18 elderly patients (3 SVR+, 4 SVR- and 9 untreated patients). In conclusion, selected elderly patients can achieve comparable SVR rates as younger patients, but with a higher rate of side effects. Since complications of HCV infection occur more frequently in elderly patients, they should be given priority for antiviral therapy.

Ključne riječi
Hepatitis C, chronic – treatment; End stage liver disease; Aged; Hepatitis C – prognosis; Pe-gylated interferon alpha; Immunotherapy

Hrčak ID: 201662

URI
https://hrcak.srce.hr/201662

[hrvatski]

Posjeta: 309 *